APP Pharmaceuticals

63 articles about APP Pharmaceuticals

• APP Pharmaceuticals Acquires Three Products from Nexus

  5/23/2012

• APP Pharmaceuticals Announces Expanded Supply of Methotrexate Injection, USP

  3/5/2012

• APP Pharmaceuticals Announces Approval of Preservative-Free Methotrexate Injection, USP

  2/22/2012

• APP Pharmaceuticals Announces Launch of Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP

  2/8/2012

• The Medicines Company Settles Angiomax(R) (Bivalirudin) Patent Litigations With APP Pharmaceuticals

  1/23/2012

• APP Pharmaceuticals Announces Increased Availability of APP Diprivan(R) and APP Propofol 1%

  10/17/2011

• APP Pharmaceuticals Announces Approval and Launch of Clonidine Hydrochloride Injection

  7/11/2011

• APP Pharmaceuticals Announces Approval of Nafcillin for Injection, USP

  7/6/2011

• APP Pharmaceuticals Invests $38 Million to Expand Its Grand Island, New York Manufacturing Facility; 90 New Jobs Will be Created

  6/15/2011

• APP Pharmaceuticals Named NOVAPLUS(R) Pharmacy Manufacturer of the Year

  6/8/2011

• APP Pharmaceuticals to Market Letrozole Tablets, USP in the U.S.

  6/7/2011

• APP Pharmaceuticals Receives Approval for Piperacillin and Tazobactam for Injection

  6/1/2011

• APP Pharmaceuticals Announces Approval and Launch of Gemcitabine HCI for Injection, USP in 2 Gram Dosage Form

  5/19/2011

• APP Pharmaceuticals Issues A Nationwide Voluntary Recall Of Irinotecan Hydrochloride Injection

  3/28/2011

• Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 25 to Delist and Deregister Contingent Value Rights for APP Pharmaceuticals

  3/8/2011

• Fresenius Kabi Pharmaceuticals Holding, Inc. Files Form 10-K for APP Pharmaceuticals

  2/23/2011

• APP Pharmaceuticals Announces Approval and Launch of Topotecan for Injection

  11/30/2010

• APP Pharmaceuticals Announces Approval of Metoprolol Tartrate Injection, USP

  11/1/2010

• The Medicines Company Announces APP Pharmaceuticals Motion to Intervene Denied

  9/10/2010

• APP Pharmaceuticals Announces Marketing Clearance of Preservative-Free Heparin Lock Flush Solution, USP

  7/6/2010